What is the trade name of tepotinib? Comparison of domestic and foreign versions

Tepotinib is a targeted drug specifically designed to target NSCLC caused by MET exon 14 skipping mutations. Its trade name is Tepmetko. The drug is the world's first oral MET inhibitor approved to treat this type of mutation. Tepmetko was first approved in Japan in 2020, and then successively received approval from European and American countries, and gradually expanded its listing areas around the world. The mechanism of Tepotinib is to interfere with the proliferation and migration of tumor cells by highly selectively inhibiting the activity of MET receptor tyrosine kinase, thereby achieving the purpose of controlling tumor growth.

In the domestic market, tepotinib has been introduced by the original drug company and officially launched in recent years. The trade name is also Tepmetko, and it was included in the medical insurance catalog in a relatively short period of time. Its specifications are usually 250mg tablets, usually taken once a day, and its simple administration method also makes it one of the more popular choices in clinical practice. However, because it is still an original brand drug, its price is relatively high. One box costs about more than 30,000 yuan, which is a heavy burden for most ordinary families. Although medical insurance can partially alleviate the financial pressure, it still poses practical challenges to many patients.

In foreign countries, especially in Southeast Asia, generic versions of Tepotinib have been released, among which the products of pharmaceutical companies represented by Laos are more prominent, including Lao Lucius Pharmaceuticals, Lao Daxiong Pharmaceuticals, Lao ASEAN Pharmaceuticals and other companies, which have all produced and sold generic versions of TepotinibTepotinib. These generic drugs are usually highly consistent with the original drugs in terms of dosage specifications, ingredient composition and efficacy, and meet basic drug quality standards. In particular, Lucius Pharmaceuticals of Laos has long been focusing on the field of generic tumor targeted drugs and has a high reputation in the local market.

Reference materials:https://www.tepotinib.com/